DLA Piper advises doc.ai in partnership with Anthem, Inc., to launch AI data trial

DLA Piper represented doc.ai, a blockchain-based artificial intelligence (AI) platform that connects people, data scientists, developers and the healthcare industry to improve patients' future health outcomes, in its partnership with health benefits company Anthem, Inc., to launch a groundbreaking AI data trial on the blockchain.

The 12-month trial will begin in August and explore whether AI can be used to predict when people will experience allergies or allergy patterns. To do so, doc.ai and advisors from Harvard Medical School will develop a framework for using machine learning to identify predictive models for allergies based upon the phenome (e.g., age, height, weight), exposome (e.g., exposure to weather/pollution based on location) and physiome (e.g., physical activity, daily steps) data collected from participating Anthem employees and members of the public. Participants will help accelerate research and benefit from the system's personalized health insights.

"Anthem is focused on leading our industry in the safe and responsible use of artificial intelligence and emerging technologies to create a better healthcare future for all Americans," said Gail K. Boudreaux, president and chief executive officer of Anthem. "We are pleased to partner with doc.ai on this innovative study that can have near-term benefit for our employees and, longer-term, the potential to redefine how we treat disease and manage chronic medical conditions to achieve better personalized health outcomes."

The allergy data trial with Anthem is the first in a series of trials doc.ai expects to host in the coming months to accelerate medical research in multiple areas including epilepsy, Crohn's Disease, Lyme disease and pain management.

DLA Piper previously represented doc.ai in its offering of Simple Agreements for Future Tokens (SAFTs). In the offering, doc.ai raised approximately US$10 million to build a smart contract-enabled network of individuals, research organizations, data scientists and others.

The DLA Piper deal team advising doc.ai included partners Louis Lehot and Sherman Chu, associate Evan Youngstrom and law clerk Daniela Pardo (all Silicon Valley).


About doc.ai
doc.ai enables consumers to take control over their health data to develop precise, personalized omics-based models that can be used to predict and change future health outcomes. The doc.ai AI platform is built on the blockchain and enables deep learning computations on quantified biology to develop personal health insights and predictive models. For more information, please visit https://www.doc.ai/. You can access the data trial at https://my.doc.ai/. The app is available as an iOS app.

Full press release about the announcement.